MedTrace Logo

ATRA for Management of Primary ITP

NCT07597395 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2026-05-19

No results posted yet for this study

Summary

A multicenter, randomized, double-blind placebo-controlled study to report the efficacy and safety of all-trans etinoic acid compared to placebo for the treatment of adults with corticosteriod-resistant/relapsed primary immune thrombocytopenia (ITP).

Conditions

Interventions

DRUG

all-trans retinoic acid (ATRA)

10mg twice daily ×24 weeks

DRUG

Placebo

10mg twice daily ×24 weeks

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Beijing Tongren Hospital

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Peking University People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-30
Primary Completion
2027-12-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07597395 on ClinicalTrials.gov